Attention Laurel Patients:  The new Laurel office is open. The address is 7140 Contee Road, Suite 3500, Laurel, MD 20707….Attention Lanham Patients: Our new Largo office will be opening Monday,  June 17th and our Lanham location will be closed permanently. Largo’s address is 9333 Healthcare Way Suite 4100 Largo, MD 20774.

Search Results

Website Search

Found 323 Results

June 20, 2024

What Black Women Need to Know About Breast Cancer Risk Breast cancer is the most commonly diagnosed cancer in Black women. And while Black women have an overall lower breast cancer incidence rate than white women, Black women under the age of 40 are more likely to be diagnosed with breast cancer than white women…

Read More

Jody has worked as a nurse practitioner in breast surgical oncology with Maryland Oncology since 2021. She graduated with her Associates of Science degree in nursing in 2006 followed by her BSN in 2008. She completed her undergraduate studies in Pennsylvania and her Masters of Science degree in nursing at George Washington University. The majority…

Read More

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer

Read More

A PHASE III RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY

Read More

Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors 

Read More

A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Read More